HTG Investment Advisors’s AbbVie ABBV Stock Holding History

HTG Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Hold	979	–	–	0.06%	80
2026 Q1	$213K	Buy	979 +5	+0.5%	+$1.11K	0.06%	80
2025 Q4	$223K	Hold	974	–	–	0.07%	72
2025 Q3	$226K	Buy	+974	New	+$198K	0.08%	70
2025 Q2	–	Sell	-974	Closed	-$204K	–	71
2025 Q1	$204K	Buy	+974	New	+$189K	0.09%	68
2024 Q4	–	Sell	-1,050	Closed	-$207K	–	66
2024 Q3	$207K	Buy	+1,050	New	+$196K	0.1%	63

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

HTG Investment Advisors's ABBV Position: Q2 2026 in Review

HTG Investment Advisors held its AbbVie (ABBV) position steady in Q2 2026 at 979 shares worth $246K. The position accounts for 0.06% of the portfolio, ranked #80.

HTG Investment Advisors first reported a position in ABBV in Q3 2024 and has held it in 6 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

HTG Investment Advisors held 979 shares of AbbVie worth $246K as of Q2 2026.
HTG Investment Advisors left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.06% of HTG Investment Advisors's portfolio in Q2 2026, its #80 holding.
HTG Investment Advisors first reported a position in AbbVie in Q3 2024 and has held it in 6 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on HTG Investment Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.